相关实验视频

Updated: Jun 26, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

在慢性髓性白血病中无治疗缓解

Garrett Bourne¹, Ravi Bhatia¹, Omer Jamy¹

¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Journal of clinical medicine

|May 11, 2024

概括

患有慢性髓性白血病 (CML) 的患者可能在停止使用氨酸激酶抑制剂 (TKIs) 后实现无治疗缓解 (TFR). 虽然TFR资格是严格的,但成功率是有希望的,如果缓解失败,重新启动TKI是安全的.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

氨酸激酶抑制剂 (TKIs) 显著改善了慢性髓性白血病 (CML) 患者的生存率.
终身TKI治疗给人带来了相当大的身体和财务负担.
无治疗缓解 (TFR) 是选择CML患者的一个新兴目标.

研究的目的:

评估慢性髓性白血病 (CML) 无治疗缓解 (TFR) 的可行性和结果.
评估在符合条件的CML患者中停止使用氨酸激酶抑制剂 (TKI) 的安全性和有效性.
通过风险分层和优化前期治疗来探索增加TFR候选人的策略.

主要方法:

审查最近的临床试验,调查CML患者的TFR.
分析TFR资格标准,包括响应的深度和持续时间.
在TKI重新启动时评估持续的TFR率和结果.

主要成果:

目前,TFR资格仅限于一小部分CML患者,这些患者对TKI有深度和持续的反应.
试验中持续的TFR率在38%至54%之间.
重新启动TKIs对于那些没有维持TFR的患者非常有效,罕见的疾病进展或死亡.

结论:

对于精选的一组CML患者来说,TFR是一种可行的和安全的选择,可以从终身TKI治疗中获得潜在的缓解.
需要进一步的研究来完善患者选择和优化预先治疗,以扩大TFR资格.
TKI重新启动的安全概况支持在CML管理中考虑TFR试验.

关键词:

慢性骨髓性白血病慢性骨髓性白血病没有治疗的缓解缓解.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...